Analysts at StockNews.com initiated coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the basic materials company’s stock.
A number of other research analysts have also commented on RKDA. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Arcadia Biosciences in a research note on Wednesday, August 21st. Lake Street Capital upgraded shares of Arcadia Biosciences to a “strong-buy” rating in a research note on Tuesday, May 14th.
Get Our Latest Report on Arcadia Biosciences
Arcadia Biosciences Price Performance
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing the consensus estimate of $1.27 by ($0.49). The firm had revenue of $1.31 million for the quarter, compared to analyst estimates of $0.95 million. Arcadia Biosciences had a negative return on equity of 57.51% and a negative net margin of 127.29%. During the same quarter in the prior year, the firm earned ($2.64) earnings per share. As a group, analysts expect that Arcadia Biosciences will post -1.7 EPS for the current year.
About Arcadia Biosciences
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Further Reading
- Five stocks we like better than Arcadia Biosciences
- 3 Healthcare Dividend Stocks to Buy
- Emerging Markets: What They Are and Why They Matter
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Recession or Not, These 3 Stocks Are Winners
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.